Martine Rothblatt, who serves as Chairperson and CEO of United Therapeutics Corp (NASDAQ: UTHR), recorded a sale of common stock totaling $5,031,117 on March 18, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the sales were executed under a pre-established 10b5-1 trading arrangement and covered trades at prices between $522.879 and $539.9875.
The filing specifies that Rothblatt disposed of 9,298 shares in a sequence of transactions carried out that day. In parallel, Rothblatt exercised stock options to acquire 9,500 shares at an exercise price of $146.03 per share, representing a total option exercise cost of $1,387,285.
After completing both the option exercise and the sales, Rothblatt directly holds 40,513 shares of United Therapeutics common stock. The filing also notes additional indirect ownership through various family trusts.
Context in the stock and company activity
The insider transactions occurred as United Therapeutics shares were trading near their 52-week high of $548, reflecting a roughly 66% gain over the prior 12 months. The company, with a market capitalization reported at $23.1 billion in the filing context, is trading at a price-to-earnings ratio of 19. InvestingPro analysis cited in the filing indicates the stock is slightly overvalued relative to its Fair Value, and points to an 88% gross profit margin among the company’s notable metrics. InvestingPro is further referenced as the source for additional valuation measures and 13 supplemental ProTips for investors.
Alongside the equity transactions, United Therapeutics has reported meaningful operational and capital allocation developments. The phase 3 TETON-2 clinical study results were published in the New England Journal of Medicine, showing that nebulized Tyvaso met the study's primary endpoint by delivering a statistically significant improvement in lung function versus placebo in patients with idiopathic pulmonary fibrosis.
The company also announced a $2 billion share repurchase program. Under the program, $1.5 billion is earmarked for accelerated share repurchase agreements with Citibank, while the remaining $500 million is reserved for further buybacks at the company’s discretion.
Analyst reactions noted in the filing include Cantor Fitzgerald raising its price target to $625 while maintaining an Overweight rating, citing expectations tied to the TETON-1 trial. TD Cowen reiterated a Buy rating and set a $575 price target, reflecting continued confidence in the company’s franchise.
Summary of the transactions and recent corporate developments
- Rothblatt sold 9,298 shares on March 18, 2026 under a 10b5-1 plan for $5,031,117, at prices between $522.879 and $539.9875.
- On the same date she exercised options to acquire 9,500 shares at $146.03 each, costing $1,387,285.
- Post-transactions direct share ownership totals 40,513 shares, with additional indirect holdings via family trusts.
- United Therapeutics reported positive phase 3 TETON-2 results and launched a $2 billion repurchase program including $1.5 billion in accelerated repurchases with Citibank.
- Analysts from Cantor Fitzgerald and TD Cowen adjusted their coverage and price targets, reflecting optimism about upcoming clinical expectations and the company’s franchise.
Implications for investors and markets
The SEC filing documents routine insider activity conducted under a pre-arranged trading plan and an option exercise, both of which are common mechanisms executives use to manage compensation and tax timing. The transactions coincide with a period of strong share performance and significant company updates in both clinical development and capital allocation. While the filing and accompanying notes present valuation commentary and analyst actions, the disclosure itself does not provide new guidance on future operations or financial results.